Article Information
History
- March 3, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Michael S. Seaman*,1,2,
- Mark J. Siedner*,3,2,
- Julie Boucau*,4,2,
- Christy L. Lavine1,
- Fadi Ghantous1,
- May Y. Liew3,
- Josh Mathews3,
- Arshdeep Singh3,
- Caitlin Marino4,
- James Regan5,
- Rockib Uddin3,
- Manish C. Choudhary5,
- James P. Flynn5,
- Geoffrey Chen3,
- Ashley M. Stuckwisch3,
- Taryn Lipiner3,
- Autumn Kittilson5,
- Meghan Melberg5,
- Rebecca F. Gilbert3,
- Zahra Reynolds3,
- Surabhi L. Iyer3,
- Grace C. Chamberlin3,
- Tammy D. Vyas3,
- Jatin M. Vyas3,2,
- Marcia B. Goldberg3,2,
- Jeremy Luban+,6,4,7,
- Jonathan Z. Li+,5,
- Amy K. Barczak+,3,4 and
- Jacob E. Lemieux+,2,3,7,†
- 1Beth Israel Deaconess Medical Center, Boston, MA
- 2Harvard Medical School, Boston, MA
- 3Massachusetts General Hospital, Boston, MA, USA
- 4Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
- 5Brigham and Women’s Hospital Boston, MA, USA
- 6UMass Med School, Worcester, MA, USA
- 7Broad Institute, Cambridge, MA, USA
- ↵†Correspondence: lemieux{at}broadinstitute.org
Posted March 03, 2022.
Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses
